Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
The AD8 Test, formally known as the Eight-item Informant Interview to Differentiate Aging and Dementia, is a brief cognitive screening tool designed to detect early signs of cognitive decline and distinguish between normal aging and mild dementia. Developed by Washington University, it addresses a critical gap in dementia care: identifying people in the early stages of cognitive impairment when intervention may be most effective. The test works by asking eight questions about changes in memory, orientation, judgment, and daily functioning—typically answered by someone who knows the person well, though patients can also complete it themselves. For example, a spouse might notice that a previously independent partner has become confused about dates or has started having trouble managing finances; the AD8 systematically captures these real-world functional changes rather than relying on abstract cognitive testing alone. What makes the AD8 valuable is its simplicity and practicality.
Unlike comprehensive neuropsychological evaluations that require hours and specialized training, the AD8 takes roughly three minutes to complete and can be administered in a doctor’s office, over the phone, or even in an emergency department. It requires no special training, making it accessible to primary care physicians and other clinicians who encounter older adults but may not be specialists in dementia. The tool has been validated across diverse populations and has demonstrated strong performance in identifying people at risk for cognitive impairment, yet it remains underutilized in many clinical settings—partly because not all clinicians are familiar with its strengths and limitations. Understanding the AD8 means recognizing both its power as a screening instrument and its boundaries as a tool that flags risk rather than confirms diagnosis. This article explores what the AD8 actually measures, how it performs in real-world settings, when it helps most, and what happens after a positive screen.
Table of Contents
- What Is the AD8 and How Does It Measure Daily Function?
- How Is the AD8 Administered and Scored?
- Clinical Validation and Diagnostic Accuracy
- Using the AD8 in Clinical Practice
- Important Limitations and When the AD8 Misses the Mark
- Comparing AD8 with Other Cognitive Screening Tools
- Recent Findings and Future Directions
- Conclusion
What Is the AD8 and How Does It Measure Daily Function?
The ad8 consists of eight yes-or-no questions that an informed observer—typically a family member, caregiver, or close friend—answers based on whether they have noticed changes in the person’s cognitive abilities over the past several years. The questions target core areas of daily functioning: memory (particularly forgetfulness and repeated questions), orientation (confusion about dates or locations), judgment (poor decision-making), and the ability to handle everyday tasks. Rather than testing what someone remembers or knows at a given moment, the AD8 assesses whether their cognitive abilities have deteriorated—a shift that family members often notice before the person themselves does. This informant-based approach is a strength because it captures functional decline in real-world contexts, not just performance on a test. The connection between cognitive impairment and daily function is direct: as cognitive abilities decline, people struggle with activities that depend on those abilities.
Someone with early memory loss might forget appointments or repeat the same stories to the same person multiple times. Judgment problems might manifest as poor financial decisions or difficulty planning meals. Disorientation could appear as getting lost in familiar places or confusion about what day it is. By asking about these observable changes, the AD8 indirectly measures cognitive status through its functional consequences. This is why the tool is particularly effective at detecting impairment in high-functioning individuals who might score normally on traditional cognitive tests but are nonetheless experiencing meaningful decline relative to their baseline.
How Is the AD8 Administered and Scored?
The AD8 is structured as a straightforward interview or written questionnaire. An informant or the patient themselves answers eight questions, with responses marked as “yes” (indicating a change) or “no” (indicating no change). The scoring is equally simple: responses are summed to create a total score ranging from 0 to 8. Historically, the cutoff has been a score of 2 or greater, interpreted as suggesting possible cognitive impairment. However, recent research has raised important questions about this threshold. A re-evaluation study published in PLOS One in May 2025 found that using a cutoff of 4 actually optimizes diagnostic accuracy, yielding 77% sensitivity and 86% specificity—meaning fewer false alarms while still catching most people with genuine impairment. This discovery illustrates a critical limitation: screening tool cutoffs are not static, universal truths. They depend on the population being screened, the clinical context, and what trade-offs are acceptable.
In a primary care setting where you want to catch everyone at risk (even if it means some false positives), a lower cutoff might be appropriate. In an emergency department where resources are limited and unnecessary workup is costly, a higher cutoff reduces overtesting. The original cutoff of 2, while highly sensitive, may produce unacceptably high false positive rates—meaning many people without actual cognitive impairment would be flagged for further evaluation. Understanding this nuance is essential for clinicians interpreting AD8 results and for families understanding what a score actually means. The AD8 can be administered in various formats: in person at a clinic visit, over the phone (which is important for patients who are homebound or live far from medical centers), or as a written self-administered questionnaire. Training is not required, which democratizes its use across healthcare settings. However, the quality of information depends heavily on who is answering. An informant who spends time with the person regularly and knows their baseline abilities provides more accurate information than someone who sees them infrequently or doesn’t know how they functioned years earlier.
Clinical Validation and Diagnostic Accuracy
The AD8’s development was rigorous. In its original validation studies, the tool demonstrated sensitivity greater than 84% and specificity greater than 80%. More comprehensively, diagnostic accuracy studies reported 85% sensitivity and 86% specificity when validated against the Clinical Dementia Rating (cdr), the gold standard for dementia staging. The correlation between AD8 scores and CDR scores was strong (r = 0.75), indicating that the test reliably correlates with clinician-based dementia assessment. The area under the receiver operating characteristic (ROC) curve was 0.90, a value considered excellent for discriminating between cognitively normal and impaired individuals. These numbers reflect performance under research conditions with well-characterized populations. Real-world performance can differ, as illustrated by an emergency department study published in 2024.
When the AD8 was administered by an informant in an ED setting, sensitivity dropped to 63% and specificity was 79%—still reasonable but notably lower than the original validation numbers. This gap highlights an important principle: a screening tool’s performance depends on the population, setting, and method of administration. When patients self-administered the test rather than having an informant complete it, accuracy was further reduced. For clinicians, this means that a positive AD8 in an ED setting warrants follow-up cognitive assessment, but a negative screen does not entirely rule out cognitive impairment. Validation across diverse populations strengthens confidence in the tool’s applicability. A 2024 validation study in Turkish geriatric patients confirmed the AD8’s effectiveness in a non-English-speaking population, supporting its use across cultural and linguistic contexts. This cross-cultural evidence is particularly important for brain health organizations serving immigrant communities and for global dementia research efforts.
Using the AD8 in Clinical Practice
The AD8’s main role is screening—identifying people who warrant further cognitive evaluation. It is not a diagnostic instrument. Someone who scores above the cutoff should proceed to more detailed cognitive testing, such as the Montreal Cognitive Assessment (MoCA) or a formal neuropsychological evaluation, to determine whether cognitive impairment is actually present and, if so, what type. Similarly, a person who scores below the cutoff and has no other cognitive concerns can typically be reassured and monitored over time; the AD8 can be repeated periodically in people at high risk for dementia (e.g., those with family history or other risk factors) to track for emerging changes. In primary care, the AD8 is practical for busy clinicians. It takes three minutes on average, requires no equipment, and can be incorporated into routine annual exams for older adults or into office visits when cognitive concerns are raised.
A primary care physician might administer the AD8 to a 72-year-old patient whose spouse reports that she has become forgetful, or to a man whose adult children called asking about declining judgment. A positive screen prompts referral to a specialist or more comprehensive evaluation; a negative screen with a reliable informant provides reassurance. The tool is also valuable in primary care because it normalizes cognitive screening—making it routine rather than something done only when obvious problems emerge. In specialty settings (memory clinics, neurology practices, geriatrics offices), the AD8 is often used as part of a broader assessment battery. It provides a quick, collateral history of functional change and can be compared to more detailed cognitive testing to understand the full picture of the person’s abilities and decline trajectory. Comparing a high AD8 score to a normal MoCA score, for example, might suggest subjective cognitive concerns or functional decline disproportionate to objective test performance—a pattern sometimes seen in early mild cognitive impairment.
Important Limitations and When the AD8 Misses the Mark
As a screening tool, the AD8 has real boundaries. It cannot diagnose dementia, mild cognitive impairment, or any specific disease. It indicates that cognitive change may be present and recommends further evaluation. For families hoping for a definitive answer, this can be frustrating—the AD8 raises questions but does not provide certainty. Another critical limitation is dependence on an informed informant. If the person has no close family, lives alone, or the family member answering is not reliable, the AD8 becomes much less useful. Some patients are reluctant to have family complete the form, preferring to answer self-administered, but as noted above, self-administration reduces accuracy. For people in the earliest stages of cognitive decline—when changes are subtle—an informant may not yet have noticed functional deterioration, leading to false negative results.
The original cutoff of 2 is known to produce high false positive rates, meaning many cognitively normal people score at or above this threshold. This was illustrated by the 2025 re-evaluation study, which prompted several professional organizations to recommend using a cutoff of 4 instead. However, adoption of the revised cutoff has been inconsistent, and many clinicians and labs still use the original threshold, leading to unnecessary downstream testing. Patients and families need to be aware that a positive AD8 with a score of 2–3 may represent normal aging or subjective concern rather than actual impairment. The AD8 also does not differentiate types of cognitive impairment. Someone with depression causing cognitive slowing, someone with medication side effects affecting memory, and someone with early Alzheimer disease could all score similarly on the AD8. This is why specialist evaluation is always necessary after a positive screen—to identify the cause and tailor treatment accordingly. Additionally, the AD8 was developed and validated primarily in research settings with predominantly white, educated, English-speaking populations; while international validation studies are increasing, generalization to all populations remains an area for future research.
Comparing AD8 with Other Cognitive Screening Tools
Multiple brief cognitive screening tools exist, and the AD8 occupies a particular niche. The Montreal Cognitive Assessment (MoCA) and Mini-Cognition Test are widely used, performance-based tools where the person being screened answers questions and performs tasks; they take longer (10–15 minutes) and require trained administration. The Mini-Cog, an ultra-brief test combining clock-drawing and word recall, takes only 3–5 minutes but relies on the person’s ability to perform motor and cognitive tasks. The AD8 differs fundamentally: it is informant-based, not performance-based, and it measures perceived change over time rather than current cognitive ability. This makes it complementary to performance-based tests.
A person might score normally on the MoCA (indicating normal current cognition) but have a high AD8 score (indicating decline relative to their previous level), a pattern that suggests either mild cognitive impairment not yet severe enough to affect test performance, or functional concerns disproportionate to objective deficits. The advantage of the AD8 is this focus on change and daily function—areas that matter most to patients and families. The disadvantage is that it requires a reliable informant and cannot be used alone to confirm impairment. In clinical practice, best practice involves using multiple screening tools together: the AD8 or similar informant-based tools to capture functional change, plus performance-based tools to assess current cognitive ability. This multimodal approach provides a more complete picture than any single tool.
Recent Findings and Future Directions
The 2025 re-evaluation of AD8 cutoff values represents the kind of research that refines screening tools over time. As the tool is used more widely and in more diverse settings, researchers identify ways to improve its diagnostic accuracy and applicability. The shift toward recommending a cutoff of 4 rather than 2 is particularly significant because it reduces false positive rates without substantially compromising sensitivity—meaning fewer unnecessary workups while still identifying most people with true cognitive impairment. This is the direction screening research should move: improving specificity to reduce harms from overdiagnosis and unnecessary medical workup.
Future work on the AD8 likely includes further validation in diverse populations, refinement of cutoff values for different clinical settings (primary care vs. emergency department vs. specialty practice), and investigation of whether the tool can be adapted for remote or digital administration as telehealth expands. Researchers are also exploring whether AD8 scores and rate of change in AD8 scores over time (rather than a single point-in-time score) might predict progression to dementia, which could make the tool useful not just for screening but for prognosis—information valuable for patients and families planning for the future.
Conclusion
The AD8 Test is a brief, practical screening tool that captures cognitive change through the eyes of family members and close observers—people who witness daily function in real-world contexts. It effectively identifies people at risk for cognitive impairment, particularly in primary care and outpatient settings, and its simplicity and accessibility make it a valuable addition to dementia screening. However, it is a screening tool only, not a diagnostic instrument; a positive AD8 warrants further evaluation, while a negative AD8 with a reliable informant provides reassurance but should not delay investigation if clinical suspicion remains high. For patients and families, understanding the AD8 means recognizing that it is a starting point—one that signals whether more detailed cognitive testing is needed—rather than an endpoint.
Recent research has refined our understanding of how to interpret AD8 scores, particularly the recognition that a cutoff of 4 may be more appropriate than the original cutoff of 2. If you or a loved one have concerns about cognitive change, discussing the AD8 with your physician is a practical next step. The tool takes minutes to administer, provides valuable information about perceived functional decline, and can guide appropriate further evaluation. In the context of comprehensive dementia care, it remains one of the most efficient ways to ask the question that matters most: has this person’s cognitive ability declined?.
